New report: Maryland lung cancer rates, survival and screening in line with national averages; treatment results better than average
New Report Highlights Lung Cancer’s Toll on Maryland’s Residents, Underscoring Need to Advance Research and Improve Care for All
American Lung Association’s ‘State of Lung Cancer’ report reveals new lung cancer data in Maryland
ANNAPOLIS – (November 17, 2026) – Today, the American Lung Association in Maryland released its annual “State of Lung Cancer” report, which shows the toll lung cancer takes on each state in the country. Lung cancer remains the leading cause of cancer deaths in Maryland and the U.S. Nationally, more than 229,000 people will be diagnosed with the disease this year. For Maryland, the report finds results generally in line with national averages for new lung cancer cases, survival, early-stage diagnosis and lung cancer screening, while the state performs better than average for receiving no treatment, ranking 17th out of 47 states at 18.4%.
“Overall, our report reveals positive news—more people in the U.S. are living longer after a lung cancer diagnosis than ever before, and more people are getting screened for the disease. While these findings give us hope, more must be done to end the burden of this devastating disease on families throughout Maryland,” said Aleks Casper, director of advocacy for the American Lung Association. “We need to increase screening rates among those at high risk to catch the disease early when it’s more likely to be curable, ensure access to comprehensive biomarker testing to help identify targeted treatments and improve access to clinical trials and the best lung cancer care.”
The “State of Lung Cancer” report examines key lung cancer indicators and ranks Maryland:
- 16 out of 51 in the nation for rate of new lung cancer cases, at 48.9 per 100,000. The national rate is 52.1 per 100,000. This marks an 11% improvement for Maryland over the past five years.
- 18 out of 43 in the nation for survival, at 32.2%. Most lung cancer cases are diagnosed at later stages when the cancer has spread, and treatment options are less likely to be curative. The national rate of people living five years after a lung cancer diagnosis is 31.0%. This marks a 20% improvement for the state over the past five years.
- 22 out of 47 in the nation for early diagnosis, at 29.9%. The earlier lung cancer is diagnosed, the more likely that treatments will be effective. Nationally, only 29.3% of cases are diagnosed at an early stage. This marks a 29% improvement for Maryland over the past five years.
- 17 out of 47 in the nation for lack of treatment, at 18.4%. While there are multiple reasons why people may not receive treatment after a lung cancer diagnosis, no one should go untreated because of lack of provider or patient knowledge, lung cancer stigma, fatalism after diagnosis or cost of treatment. Nationally, 20.9% of cases receive no treatment.
- 14 out of 50 in the nation for lung cancer screening, at 26.2%. Lung cancer screening with annual low-dose CT scans for people at high risk can reduce the lung cancer death rate by up to 20%. Nationally, only 24.4% of people at high risk were screened.
- 9 out of 48 in the nation for smoking, at 8.3%. Tobacco use is the leading risk factor for lung cancer. Both smoking and secondhand smoke have been shown to cause lung cancer.
- 21 out of 51 in the nation for radon, at 20.8%. Radon, a colorless and odorless gas that can be present at high levels inside homes and buildings, is the second leading cause of lung cancer. Every home should be regularly tested for radon and mitigated if results are high.
The “State of Lung Cancer” report also examines insurance coverage of comprehensive biomarker testing, which can help identify more personalized treatment options for a person’s specific type of lung cancer, including targeted therapies and immunotherapy. Insurance coverage of comprehensive biomarker testing is critical for making this test more accessible, but 24 states and Washington, D.C., do not require any coverage. The report found that Maryland does require insurance coverage of comprehensive biomarker testing.
Additionally, clinical trials are essential to improving outcomes for people affected by lung cancer and increasing survival rates. Unfortunately, too many people face barriers that prevent them from participating in and benefit from cutting edge research. The Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which includes critical steps to make clinical trials accessible to more people and advance research and care for all.
The Lung Association brings research, advocacy and health promotions together to address lung cancer, investing in science, advocating for better access to prevention and care, and providing education, support and resources to help individuals navigate timely access to screening, diagnosis and treatment.
Learn more about the “State of Lung Cancer” report and take action to help end lung cancer at Lung.org/solc.
Media Resources:
- B-Roll is available here:
- Lung Cancer Screening: LungCancerB-roll_Final.mp4 | Powered by Box
- Doctor and Patient: Broll: Doctor and patient consultation.mp4 | Powered by Box
- American Lung Association logos are available here: Media | American Lung Association
About the American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Platinum-Level GuideStar Member, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit:? Lung.org

